Global menu

Our global pages

Yang Wang, Associate

Yang Wang



Mandarin, English

Practice areas

  • Commercial agreements

Practice notes

Yang is an associate in the firm’s Beijing office. She is admitted to practice law in Texas, United States. Yang’s principal areas of practice are cross-border mergers and acquisitions, complex commercial transactions and corporate governance. Yang has advised clients across a range of industries including power, oil and gas, renewable energy, utilities, life science and healthcare.

A former investigative journalist in the U.S., Yang benefits her client with excellent analytical and communicative skills in both English and Chinese. Prior to joining Eversheds Sutherland, Yang worked for a leading international law firm in Houston, Texas. She graduated from Peking University (B.A.) and University of Houston Law Center (J.D.).

Highlights of Yang’s recent experience include:

Mergers and Acquisitions

• A U.S. telecommunication company in the auction sale of all of its equity interests.

• The largest U.S. ship-building company in its $75-million-dollar bid to acquire all of the equity interest in an un-manned watercraft manufacturer.

• The largest U.S. car rental company on a series of asset acquisitions from its franchisees across North America.

• A Chinese state-owned company in the acquisition and development of twelve (12) solar projects in the U.S.

• A U.S. technology company in the sale of its commercial end-to-end managed satellite and terrestrial communications division involving 26 jurisdictions for a cash price of $425 million.

• A global medical device company in acquisition of certain patents and related documentation from a Canadian company.

Complex Commercial Transactions

• A large Japanese pharmaceutical company in licensing its certain patent rights to a Chinese pharmaceutical company for the purpose of developing, manufacturing and commercializing certain drug product in China.

• A U.S. gas production joint venture in reorganizing its intellectual and production assets.

• A multinational pharmaceutical company in the negotiation of its contracts in drug research, development and commercialization.